COVID-19 Corona Virus Vaccine Medicine Development Clinical Trials in China
New development of COVID-19! New drug candidate discovered by Shanghai Institute of Pharmaceutical Research, Chinese Academy of Sciences
New development of COVID-19! The Chinese Academy of Sciences Shanghai Institute of Pharmaceutical Sciences has discovered new drug candidates, and another new vaccine has begun clinical trials.
At present, according to Yaozhi.com's "Tools for Fighting New Coronary Pneumonia-Epidemic Map", there are 2,551,464 people diagnosed with New Coronary Pneumonia infection worldwide and 179,695 deaths. It has become a global epidemic disease, and as of now, no curable special effects have been developed. Medicines and vaccines that can be prevented. But in order to overcome the virus and win the epidemic warfare, new news on the development of medicines and vaccines are constantly coming.
New Discovery of Anti-New Coronavirus Candidates in Shanghai Institute of Pharmaceutical Sciences, Chinese Academy of Sciences
On April 22, the official website of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences released news that the Liu Hong / Xu Yechun / Jiang Hualiang team of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, together with the Yang Haitao / Rao Zihe team of the Shanghai University of Science and Technology and the Lei Zhang / Xiao Gengfu team of the Wuhan Institute of Virology Cooperation, made important progress in the research of anti-coronavirus drugs.
They found a class of novel, efficient, and safe anti-SARS-CoV-2 virus drug candidates. The research results were published on the bio-preprint website bioRxiv on March 28 and published online on Science on April 22.
The official website shows that the study was based on two peptoid compounds 11a and 11b designed and synthesized based on the three-dimensional structure of the coronavirus main protease. The two compounds exhibit excellent inhibitory activity against SARS-CoV-2Mpro in vitro, and have better antiviral effects.
More importantly, both compounds exhibit good in vivo pharmacokinetic properties and safety.
Pfizer and BioNTech's COVID-19 vaccine begins clinical trials
On April 22, Pfizer and BioNTech announced that their jointly developed BNT162 vaccine received regulatory approval from the German Federal Institute for Vaccine and Biomedical Research PaulEhrlichInstitute, and began a phase 1/2 clinical trial of the potential COVID-19 vaccine in the country.
In the first phase of clinical trials, 200 volunteers between the ages of 18 and 55 will be vaccinated with different doses of vaccines to study the optimal dose of their vaccines, as well as several different vaccines. This trial is the first clinical trial of a new coronavirus candidate vaccine started in Germany and is also part of the BNT162 global development plan.
It is reported that Pfizer and BioNTech will also conduct trials in the United States and is expected to obtain regulatory approval soon. It is worth mentioning that on March 16, Fosun Pharma and BioNTech signed a license agreement for the exclusive development and commercialization of the vaccine product for COVID-19 based on its proprietary mRNA technology platform in the region. China conducts clinical trials.
Moderna New Coronavirus Vaccine Volunteer Injects Second Injection
According to the latest news from USA Today, in the first phase of the mRNA new coronavirus vaccine mRNA-1273 trial launched by Moderna in the United States last month, Seattle volunteers who received the first injection of the vaccine are now injecting the second injection.
The mRNA-1273 vaccine was jointly developed by the National Institute of Allergy and Infectious Diseases and the American biotechnology company Moderna. It is the first new crown vaccine in the United States for clinical trials. Lisa Jackson, who led the study, said that the vaccine was taken in two doses.
The first shot was a primer that activates the immune system, and the second shot was performed 28 days later. It established the protection formed by the first shot. Basically, if the human body is later exposed to the virus, it can produce antibodies more quickly.
Oxford University adenovirus vaccine will start clinical trials
On April 22, the British Minister of Health and the ChAdOx1 new coronavirus candidate vaccine developed by the University of Oxford is expected to begin its first human clinical trial on April 24.
ChAdOx1 was developed by researchers at the Oxford University’s Jenner Institute (Jenner Institute) and uses an adenovirus vaccine platform. It introduced the transgene encoding the new crown virus spike protein into the adenovirus vector. Adenovirus vector technology can stimulate a strong immune response through a single dose of vaccination. At the same time, the virus cannot replicate and will not cause infection in people who are vaccinated.
The World Health Organization released a new coronavirus
candidate vaccine that entered clinical trials on April 22.
candidate vaccine that entered clinical trials on April 22.
Author's Bio
Name: Ian Skyler
Education: MBBS, MD
Occupation: Medical Doctor
Specialization: Community Medicine, General Surgery, Natural Treatment
Experience: 18 Years as a Medical Practitioner
Share this in Public Information Interest>>
Comments
Post a Comment